Corona Remedies Ltd IPO Subscription Status


    Source:
    BSE Last Updated: As per exchange snapshot available at 15:59 PM on December 10, 2025

    Corona Remedies IPO: Subscription Status & Key Highlights

    The Corona Remedies Ltd IPO opened on December 10, 2025 and recorded participation across retail, NII, and employee categories today. The QIB (ex-anchor) segment showed early-phase activity, while the anchor allocation was completed prior to the issue opening.

    Monitoring category-wise subscription updates helps understand how different investor groups participate over the subscription period. The figures below reflect the status as per the latest exchange snapshot available at the time of reporting.

    Corona Remedies IPO Subscription Status

    As of December 10, 2025 (15:59 PM)

    Overall subscription: 141.99×
    (Actual figures may vary with live exchange updates; readers should refer to the BSE/NSE book for the latest numbers.)

    Category-Wise Subscription Snapshot

    Investor Category

    Subscription (times)

    Shares Offered*

    Shares bid for

    Total Amount (Rs Cr.)*

    Anchor Investors

    1

    18,34,804

    18,34,804

    194.86

    QIB (Ex Anchor)

    290.30

    12,21,729

    35,46,63,358

    37,665.25

    Non-Institutional Buyers

    218.65

    9,16,960

    20,04,92,698

    21,292.32

    bNII (bids above ₹10L)

    246.36

    6,11,307

    15,06,00,856

    15,993.81

    sNII (bids below ₹10L)

    163.23

    3,05,653

    4,98,91,842

    5,298.51

    Retail Investors

    27.90

    21,39,573

    5,97,00,802

    6,340.23

    Employees

    14.41

    58,036

    8,36,010

    88.78

    Total **

    141.99

    43,36,298

    61,56,92,868

    65,386.58

    Total Applications Received: 38,75,507
    *Calculated at the upper end of the price band.
    **Anchor portion excluded from the “Total” shares offered.

    Corona Remedies IPO – Issue Details

    • Total Issue Size: 61,71,101 shares (₹655.37 crore)

    • Issue Type: Book-built, entirely Offer for Sale (OFS)

    • Price Band: ₹1008–₹1062 per share

    • Lot Size: 14 shares

    • Listing: BSE & NSE

    • Employee Discount: ₹54 per share

    Breakup of Shares Offered

    Category

    Shares Offered

    Amount (Rs Cr)

    Size (%)

    QIB

    30,56,533

    324.60

    49.53%

    Anchor Investor

    18,34,804

    194.86

    29.73%

    QIB (Ex Anchor)

    12,21,729

    129.75

    19.80%

    NII

    9,16,960

    97.38

    14.86%

    Retail

    21,39,573

    227.22

    34.67%

    Employee

    58,036

    6.16

    0.94%

    Total

    61,71,102

    655.37

    100%

    *Anchor forms part of the QIB quota under applicable SEBI regulations.

    Utilisation of Offer Proceeds

    Since the issue comprises an Offer for Sale, proceeds will go to the selling shareholders. The company will not receive funds from this IPO.

    Anchor Investor Allocation

    Corona Remedies Ltd raised ₹194.86 crore from anchor investors ahead of the IPO.

    Particulars

    Details

    Anchor Bid Date

    December 5, 2025

    Shares Allotted

    18,34,804

    Anchor Portion Size

    ₹194.86 crore

    Anchor Investor Price

    ₹1,062 per share

    Lock-in (30 days)

    As per SEBI ICDR norms

    Lock-in (90 days)

    As per SEBI ICDR norms

    Note: Actual lock-in distribution follows SEBI’s 30/90-day framework for anchor investors.

    Corona Remedies IPO Lot Size

    Application Type

    Lots

    Shares

    Amount (₹) at Upper Band

    Retail (Min)

    1

    14

    ₹14,868

    Retail (Max)

    13

    182

    ₹1,93,284

    S-HNI (Min)

    14

    196

    ₹2,08,152

    S-HNI (Max)

    67

    938

    ₹9,96,156

    B-HNI (Min)

    68

    952

    ₹10,11,024

    Corona Remedies IPO – Timeline (Tentative)

    Event

    Date

    IPO Opens

    Mon, Dec 8, 2025

    IPO Closes

    Wed, Dec 10, 2025

    Allotment

    Thu, Dec 11, 2025

    Refund Initiation

    Fri, Dec 12, 2025

    Shares Credit to Demat

    Fri, Dec 12, 2025

    Listing

    Mon, Dec 15, 2025

    UPI Mandate Cut-off

    5 PM on Wed, Dec 10, 2025

    Corona Remedies Ltd – Financial Highlights

    (Restated consolidated financials as disclosed in offer documents)

    Metric (₹ crore)

    30 Jun 2025

    FY25

    FY24

    FY23

    Assets

    1,012.38

    929.86

    830.58

    595.02

    Total Income

    348.56

    1,202.35

    1,020.93

    891.10

    PAT

    46.20

    149.43

    90.50

    84.93

    EBITDA

    71.80

    245.91

    161.19

    135.03

    Net Worth

    607.02

    606.34

    480.41

    408.52

    Total Borrowing

    106.65

    62.70

    134.14

    2.33

    Key Performance Indicators

    KPI

    Value

    ROE

    27.50%

    ROCE

    41.32%

    Debt/Equity

    0.10

    RoNW

    24.65%

    PAT Margin

    12.49%

    EBITDA Margin

    20.55%

    P/BV

    10.71

    About the Company

    Incorporated in 2004, Corona Remedies Ltd operates across therapeutic segments including women’s healthcare, cardio-diabeto, urology, and pain management.
    As of June 30, 2025, the company had:

    • 71 brands,

    • 2,671 medical representatives,

    • Operations across 22 states, and

    • Two manufacturing facilities in Gujarat with an installed capacity of 1,285.44 million units annually.

    Conclusion

    The Corona Remedies IPO witnessed participation across retail, NII, and employee categories today, with anchor activity concluded ahead of the opening. Subscription levels may continue to evolve through the bidding period. Investors should track real-time updates directly from the exchanges for the latest book status.

    Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Corona Remedies.

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Publish Date: 09 Dec 2025

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    1 M+ Users

    4.8 App Rating

    4 Languages

    ₹7,300 Cr+ MTF Book

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |